Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor

Journal of Hepatology

Volumn 60, Issue 4, 2014, Pages 723-731

  Nkongolo, Shirin ^a   Ni, Yi ^a   Lempp, Florian A ^a   Kaufman, Christina ^a   Lindner, Thomas ^a   Esser Nobis, Katharina ^a   Lohmann, Volker ^a   Mier, Walter ^a   Mehrle, Stefan ^a   Urban, Stephan ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Binding domain; Cyclosporin A; Hepatitis B; Hepatitis D; Immunosuppressive; Myrcludex B; Sodium taurocholate cotransporting polypeptide; Tacrolimus; Viral entry

Indexed keywords

CALCINEURIN; CYCLOPHILIN; CYCLOPHILIN A; CYCLOPHILIN B; CYCLOSPORIN A; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HEPATITIS DELTA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; MYRCLUDEX B; SODIUM BILE ACID COTRANSPORTER; TACROLIMUS; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; COTRANSPORTER; CYCLOSPORIN; LIPOPEPTIDE; MUTANT PROTEIN; MYRCLUDEX-B; ORGANIC ANION TRANSPORTER; SODIUM-BILE ACID COTRANSPORTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DELTA AGENT HEPATITIS; DRUG BINDING SITE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; HEPATITIS B; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE; IMMUNOSUPPRESSIVE TREATMENT; LIMIT OF QUANTITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSIENT TRANSFECTION; TREATMENT DURATION; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS INHIBITION; VIRUS INTERFERENCE; ANTAGONISTS AND INHIBITORS; BINDING SITE; CELL CULTURE; CELL LINE; DRUG EFFECTS; GENETIC VARIABILITY; GENETICS; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HEPG2 CELL LINE; HOST PATHOGEN INTERACTION; METABOLISM; PATHOGENICITY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

BINDING SITES; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; CYCLOPHILINS; CYCLOSPORINE; GENETIC VARIATION; HEP G2 CELLS; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; LIPOPEPTIDES; MUTANT PROTEINS; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; PROTEIN STRUCTURE, TERTIARY; SYMPORTERS; TACROLIMUS; VIRUS INTERNALIZATION;

EID: 84896394502     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.11.022     Document Type: Article

References (38)

1. C. Seeger, and W.S. Mason Hepatitis B virus biology Microbiol Mol Biol 64 2000 51 68
2. D. Glebe, and S. Urban Viral and cellular determinants involved in hepadnaviral entry World J Gastroenterol 13 2007 22 38
3. A. Meier, S. Mehrle, T.S. Weiss, W. Mier, and S. Urban Myristoylated preS1-domain of the hepatitis B virus l-protein mediates specific binding to differentiated hepatocytes Hepatology 58 2013 31 42
4. P. Gripon, J. Le Seyec, S. Rumin, and C. Guguen-Guillouzo Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity Virology 213 1995 292 299
5. J. Le Seyec, P. Chouteau, I. Cannie, C. Guguen-Guillouzo, and P. Gripon Infection process of the hepatitis B virus depends on the presence of a defined sequence in the pre-s1 domain J Virol 73 1999 2052 2057
6. M. Blanchet, and C. Sureau Infectivity determinants of the hepatitis B virus pre-s domain are confined to the n-terminal 75 amino acid residues J Virol 81 2007 5841 5849
7. H. Yan, G. Zhong, G. Xu, W. He, Z. Jing, and Z. Gao et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus Elife 1 2012 e00049
8. G.A. Kullak-Ublick, B. Stieger, and P.J. Meier Enterohepatic bile salt transporters in normal physiology and liver disease Gastroenterology 126 2004 322 342
9. S.A. Azer, and N.H. Stacey Differential effects of Cyclosporin A on the transport of bile acids by human hepatocytes Biochem Pharmacol 46 1993 813 819
10. Z. Dong, S. Ekins, and J.E. Polli Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP) Mol Pharm 10 2013 1008 1019
11. +/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs Drug Metab Dispos 34 2006 1575 1581
12. K. Watashi, M. Hijikata, M. Hosaka, M. Yamaji, and K. Shimotohno et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes Hepatology 38 2003 1282 1288
13. F. Fernandes, D.S. Poole, S. Hoover, R. Middleton, A.-C. Andrei, and J. Gerstner et al. Sensitivity of hepatitis C virus to cyclosporine a depends on nonstructural proteins NS5A and NS5B Hepatology 46 2007 1026 1033
14. P. Gripon, S. Rumin, S. Urban, J. Le Seyec, D. Glaise, and I. Cannie et al. Infection of a human hepatoma cell line by hepatitis B virus Proc Natl Acad Sci U S A 99 2002 15655 15660
15. Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Fälth M, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide (NTCP) for entering hepatocytes in a species-specific manner. Gastroenterology 2013. http://dx.doi.org/10.1053/j.gastro.2013.12.024.
16. A. Kaul, S. Stauffer, C. Berger, T. Pertel, J. Schmitt, and S. Kallis et al. Essential role of cyclophilin a for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics PLoS Pathog 5 2009 e1000546
17. K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method Methods 25 2001 402 408
18. C. Lepère-Douard, M. Trotard, J. Le Seyec, and P. Gripon The first transmembrane domain of the hepatitis B virus large envelope protein is crucial for infectivity J Virol 83 2009 11819 11829
19. S. Gaali, C. Kozany, B. Hoogeland, M. Klein, and F. Hausch Facile synthesis of a fluorescent cyclosporin a analogue to study cyclophilin 40 and cyclophilin 80 ligands ACS Med Chem Lett 1 2010 536 539
20. Y.A. Kim, A. Sharon, C.K. Chu, R.H. Rais, O.N. Al Safarjalani, and F.N. Naguib et al. Synthesis, biological evaluation and molecular modeling studies of N6-benzyladenosine analogues as potential anti-toxoplasma agents Biochem Pharmacol 73 2007 1558 1572
21. M.J. Bouchard, R.J. Puro, L. Wang, and R.J. Schneider Activation and inhibition of cellular calcium and tyrosine kinase signaling pathways identify targets of the HBx protein involved in hepatitis B virus replication J Virol 77 2003 7713 7719
22. M. Rizzetto Hepatitis D: thirty years after J Hepatol 50 2009 1043 1050
23. +-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells Am J Physiol Gastrointest Liver Physiol 274 1998 G370 G375
24. S. Ho, N. Clipstone, L. Timmermann, J. Northrop, I. Graef, and D. Fiorentino et al. The mechanism of action of cyclosporin A and FK506 Clin Immunol Immunopathol 80 1996 S40 545
25. L.A. Gaither, J. Borawski, L.J. Anderson, K.A. Balabanis, P. Devay, and G. Joberty et al. Multiple cyclophilins involved in different cellular pathways mediate HCV replication Virology 397 2010 43 55
26. P. Wang, and J. Heitman The cyclophilins Genome Biol 6 2005 226
27. B. Döring, T. Lütteke, J. Geyer, and E. Petzinger The SLC10 carrier family: transport functions and molecular structure Curr Top Membr 70 2012 105 168
28. H. Yan, B. Peng, W. He, G. Zhong, Y. Qi, and B. Ren et al. Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide J Virol 87 2013 7977 7991
29. A. Schulze, A. Schieck, Y. Ni, W. Mier, and S. Urban Fine mapping of pre-s sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction J Virol 84 2010 1989 2000
30. +-dependent taurocholate co-transporting protein Biochem J 441 2012 1007 1015
31. R. Elsner, and K. Ziegler Determination of the apparent functional molecular mass of the hepatocellular sodium-dependent taurocholate transporter by radiation inactivation Biochim Biophys Acta 983 1989 113 117
32. B.D. Kahan, S.M. Flechner, M.I. Lorber, C. Jensen, D. Golden, and C.T. Van Buren Complications of cyclosporin therapy World J Surg 10 1986 348 360
33. R. Schade, A. Gugliemi, D. Van Thiel, M. Thompson, V. Warty, and B. Griffith et al. Cholestasis in heart transplant recipients treated with cyclosporine Transplant Proc 15 1983 2757 2760
34. B.G. Stone, M. Udani, A. Sanghvi, V. Warty, K. Plocki, and C.D. Bedetti et al. Cyclosporin A-induced cholestasis. The mechanism in a rat model Gastroenterology 93 1987 344 351
35. T. Steinmüller, D. Seehofer, N. Rayes, A.R. Müller, U. Settmacher, and S. Jonas et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease Hepatology 35 2002 1528 1535
36. U.P. Neumann, J.M. Langrehr, U. Naumann, M. Lang, N. Rayes, and T. Steinmüller et al. Impact of HLA-compatibilities in patients undergoing liver transplantation for HBV-cirrhosis Clin Transplant 16 2002 122 129
37. S. Beckebaum, G.C. Sotiropoulos, C.G. Klein, C.E. Broelsch, F. Saner, and A. Paul et al. Predictive factors of outcome in patients transplanted for hepatitis B Transplantation 27 2009 872 881
38. R.G. Morris Cyclosporin therapeutic drug monitoring - an established service revisited Clin Biochem Rev 24 2003 33 46